Free Trial

20 Stocks Wall Street Analysts Love the Most - 6 of 20

 
 

AptarGroup (NYSE:ATR)

Consensus Rating
Buy
Rating Score
3.2
Ratings Breakdown
5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$195.00 (14.5% Upside)

About AptarGroup

AptarGroup logoAptarGroup, Inc designs and manufactures a range of drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, beauty, personal care, home care, and food and beverage markets. The company operates through Aptar Pharma, Aptar Beauty, and Aptar Closures segments. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
10/28/2024Robert W. BairdBoost Price TargetOutperform ➝ Outperform$170.00 ➝ $185.00
10/16/2024Dbs BankUpgradeHold ➝ Strong-Buy
10/15/2024Wells Fargo & CompanyBoost Price TargetOverweight ➝ Overweight$168.00 ➝ $185.00
10/14/2024Jefferies Financial GroupUpgradeHold ➝ Buy$155.00 ➝ $215.00
7/17/2024Wells Fargo & CompanyBoost Price TargetOverweight ➝ Overweight$163.00 ➝ $168.00
4/29/2024Wells Fargo & CompanyBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $163.00
4/29/2024William BlairUpgradeMarket Perform ➝ Outperform
4/29/2024Robert W. BairdBoost Price TargetOutperform ➝ Outperform$150.00 ➝ $170.00
3/7/2024Wells Fargo & CompanyBoost Price TargetOverweight ➝ Overweight$157.00 ➝ $160.00
1/3/2024Robert W. BairdUpgradeNeutral ➝ Outperform$125.00 ➝ $150.00
 

NASDAQ traded stock with a BIG short position. (Ad)

Small cap NASDAQ firm is an innovative leader in non-opioid pain therapeutics. The company’s offerings could significantly aid in stopping the opioid crisis and create maximum shareholder growth!

See how this NASDAQ Bio-tech is offering viable solutions